Moderna revealed the consequences of its late start in the market for RSV vaccines, reporting just $10 million in third-quarter sales from the new shot. Those numbers are a fraction ...

Sarepta Therapeutics is stopping development of vesleteplirsen, an experimental exon 51-skipping therapy for Duchenne muscular dystrophy patients with certain mutations. It's also halting work on all ...

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

California voters supported a state ballot measure on Tuesday that would increase oversight around the 340B federal drug ...

In his first quarter leading CVS Health, CEO David Joyner laid out the initial steps he’s taking to rightsize the company, as ...

Novo Nordisk disclosed several key updates from its cardiometabolic and hematology pipelines Wednesday as the drugmaker ...

As former President Donald Trump returns to power — the Associated Press projected his presidential victory Wednesday morning — the biopharma industry may see the door open wider for more dealmaking, ...

US presidential election winner Donald Trump has promised to let his ally Robert F. Kennedy Jr. “go wild” on drug and food policy. While Kennedy’s exact role in a potential ...

It took decades to get to the GLP-1 breakthrough in obesity treatment. Now, the biopharma industry is clamoring over the field's next frontier: staving off the losses ...

Response Pharmaceuticals believes its experimental drug can lessen the persistent weight gain associated with antipsychotics.

Catalent reported a slight revenue upswing during its latest quarterly results, which CEO Alessandro Maselli attributed to ...

Zealand is po­si­tion­ing the drug as a po­ten­tial stand­alone re­place­ment for GLP-1s or as the first med­i­cine that ...